Cyclacel Pharmaceuticals Statistics
Total Valuation
CYCC has a market cap or net worth of $13.16 million. The enterprise value is $9.83 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCC has 1.58 million shares outstanding.
| Current Share Class | 1.58M |
| Shares Outstanding | 1.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +55.68% |
| Owned by Insiders (%) | 73.10% |
| Owned by Institutions (%) | 0.23% |
| Float | 311,554 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,409.73 |
| Forward PS | 184.28 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 3.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 983.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.77 |
| Quick Ratio | 5.63 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -276.80% and return on invested capital (ROIC) is -278.74%.
| Return on Equity (ROE) | -276.80% |
| Return on Assets (ROA) | -102.83% |
| Return on Invested Capital (ROIC) | -278.74% |
| Return on Capital Employed (ROCE) | -284.48% |
| Revenue Per Employee | $833 |
| Profits Per Employee | -$534,000 |
| Employee Count | 12 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CYCC has paid $986,000 in taxes.
| Income Tax | 986,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.30% in the last 52 weeks. The beta is 0.09, so CYCC's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -97.30% |
| 50-Day Moving Average | 8.33 |
| 200-Day Moving Average | 61.65 |
| Relative Strength Index (RSI) | 45.79 |
| Average Volume (20 Days) | 1,853,424 |
Short Selling Information
The latest short interest is 101,016, so 6.38% of the outstanding shares have been sold short.
| Short Interest | 101,016 |
| Short Previous Month | 123,114 |
| Short % of Shares Out | 6.38% |
| Short % of Float | 32.42% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, CYCC had revenue of $10,000 and -$6.41 million in losses. Loss per share was -$4.76.
| Revenue | 10,000 |
| Gross Profit | 10,000 |
| Operating Income | -10.36M |
| Pretax Income | -22.73M |
| Net Income | -6.41M |
| EBITDA | -10.35M |
| EBIT | -10.36M |
| Loss Per Share | -$4.76 |
Full Income StatementBalance Sheet
The company has $4.28 million in cash and $10,000 in debt, giving a net cash position of $4.27 million or $2.69 per share.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 10,000 |
| Net Cash | 4.27M |
| Net Cash Per Share | $2.69 |
| Equity (Book Value) | 3.63M |
| Book Value Per Share | 2.70 |
| Working Capital | 3.62M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -103,580.00% |
| Pretax Margin | -54,220.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |